Results 201 to 210 of about 610,904 (340)
Gavi's Zero-Dose Learning Hubs: enhanced approach for evidence generation and use from local to global. [PDF]
Reynolds HW +6 more
europepmc +1 more source
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin +11 more
wiley +1 more source
Editorial: Beyond contraception - advancing research and innovations in sexual and reproductive health to better meet the needs of women in Low-and middle-income countries. [PDF]
Cordova-Gomez A, Shirima S, Nwachukwu E.
europepmc +1 more source
ABSTRACT Objective Super‐Refractory Status Epilepticus (SRSE) is a rare, life‐threatening neurological emergency with unclear etiology in many cases. Mitochondrial dysfunction, often due to disease‐causing genetic variants, is increasingly recognized as a cause, with each gene producing distinct pathophysiological mechanisms.
Pouria Mohammadi +2 more
wiley +1 more source
The South African financial services industry’s integrated reporting compliance with the global reporting initiative framework [PDF]
Pieter Buys, Eldine van Niekerk
doaj
Standardization of Administered Activities in Pediatric Nuclear Medicine: A Report of the First Nuclear Medicine Global Initiative Project, Part 1—Statement of the Issue and a Review of Available Resources [PDF]
Frederic H. Fahey +15 more
openalex +1 more source
Predicting Loss of Ambulation in Limb Girdle Muscular Dystrophy R9
ABSTRACT Background Limb girdle muscular dystrophy type R9 (LGMDR9) results from biallelic variants in FKRP. There is limited data to predict loss of ambulation (LOA) among those with LGMDR9. Methods Participants in an ongoing dystroglycanopathy natural history study (NCT00313677) with FKRP variants who had achieved ambulation and were more than 3 ...
Chandra L. Miller +6 more
wiley +1 more source

